Developing Technologies For Tomorrow’s Therapies

Caladrius leverages the manufacturing expertise of its wholly-owned subsidiary, PCT, a leading development and manufacturing partner to the cell therapy industry, to develop selected potentially disruptive cell therapies through early stage studies to their next clinical milestone (likely proof-of concept). These therapies are identified based on the Company’s constant exposure to new developments in the industry. Caladrius then seeks partners to fund and execute the balance of the development and regulatory processes. In the process, Caladrius hopes to promote revenue growth at PCT as the preferred cGMP manufacturing partner for the later-stage clinical studies and commercialization.

Product Candidates:

CLBS03 for type 1 diabetes
CLBS20 for metastatic melanoma
CLBS12 for critical limb ischemia
CLBS10 for ST-elevation myocardial infarction